STOCK TITAN

Sabby entities disclose 9.9% Oragenics (OGEN) stake in Schedule 13G

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Oragenics, Inc. received a Schedule 13G filing showing that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz together report beneficial ownership of 412,654 shares of Oragenics common stock. This position represents 9.9% of the outstanding common shares as of the filing. The reporting persons state they have shared voting and dispositive power over all 412,654 shares and no sole voting or dispositive power. They also certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Oragenics, but instead are held on a passive basis consistent with a Schedule 13G filing.

Positive

  • None.

Negative

  • None.

Insights

Sabby reports a passive 9.9% stake in Oragenics.

The filing shows Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz jointly reporting beneficial ownership of 412,654 Oragenics common shares, or 9.9% of the class. All three report shared, but not sole, power to vote and dispose of these shares, which centralizes influence over this block.

The use of a Schedule 13G and the certification language indicate the position is not intended to change or influence control of Oragenics. This makes the disclosure informational rather than strategic. Actual impact on trading or governance will depend on how this 9.9% holder chooses to vote and manage the position over time.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



SABBY MANAGEMENT, LLC
Signature:/s/ Robert Grundstein
Name/Title:COO
Date:01/21/2026
Hal Mintz
Signature:/S/ HAL MINTZ
Name/Title:HAL MINTZ
Date:01/21/2026
Sabby Volatility Warrant Master Fund, Ltd.
Signature:/s/ Harry Thompson
Name/Title: Harry Thompson
Date:01/21/2026

FAQ

What stake in Oragenics (OGEN) is reported in this Schedule 13G?

The filing reports beneficial ownership of 412,654 shares of Oragenics common stock, representing 9.9% of the outstanding common shares.

Who are the reporting persons in the Oragenics (OGEN) Schedule 13G?

The reporting persons are Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz, each reporting beneficial ownership of the same 412,654 shares.

Do the Oragenics (OGEN) Schedule 13G filers have voting and dispositive power over the shares?

Yes. The filers report 0 shares with sole voting or dispositive power and 412,654 shares with shared voting and shared dispositive power.

Is the 9.9% Oragenics (OGEN) position reported as a passive investment?

Yes. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of Oragenics, consistent with a passive Schedule 13G filing.

What class of securities is covered by this Oragenics (OGEN) Schedule 13G?

The filing covers Oragenics common stock with CUSIP 684023609.

When did the ownership level in this Oragenics (OGEN) Schedule 13G become reportable?

The filing identifies 12/31/2025 as the date of event that required submission of the Schedule 13G.
Oragenics

NYSE:OGEN

OGEN Rankings

OGEN Latest News

OGEN Latest SEC Filings

OGEN Stock Data

4.13M
4.07M
2.41%
2.56%
0.81%
Biotechnology
Pharmaceutical Preparations
Link
United States
SARASOTA